Moderna's Vaccine Produces Antibodies for at Least 6 Months
Moderna (NASDAQ: MRNA) reported data showing participants in its coronavirus vaccine trial continued to have antibodies to the virus six months later. In this video from Motley Fool Live, recorded on April 12, Fool.com Contributors Brian Orelli and Keith Speights discuss the data and the difference between antibody levels and efficacy data for infection rates.
Source Fool.com